ObsEva Announces UK MHRA Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
28 juin 2022 16h01 HE
|
ObsEva SA
-Yselty® (linzagolix) is the first and only approved GnRH antagonist to provide flexible dosing options with and without hormonal add-back therapy- -Theramex to commercialize Yselty®; ObsEva to...
ObsEva Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
17 juin 2022 07h00 HE
|
ObsEva SA
-Yselty® (linzagolix) is the first and only approved GnRH antagonist to provide flexible dosing options with and without hormonal add-back therapy- -Theramex to commercialize Yselty®; ObsEva to...
ObsEva Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
17 juin 2022 01h00 HE
|
ObsEva SA
-Yselty® (linzagolix) is the first and only approved GnRH antagonist to provide flexible dosing options with and without hormonal add-back therapy- -Theramex to commercialize Yselty®; ObsEva to...
ObsEva Presents Clinical Data on Open-Label Pilot Study of Yselty® (linzagolix) for the Treatment of Severe Adenomyosis at ESHRE Virtual 37th Annual Meeting
30 juin 2021 01h00 HE
|
ObsEva SA
-Two additional abstracts presented on data from ongoing clinical programs: Yselty for the treatment of uterine fibroids and nolasiban for uterine contractility of IVF patients prior to embryo...
ObsEva Announces Final Results from the Phase 3 PRIMROSE Program of Yselty® (linzagolix) for the Treatment of Uterine Fibroids
20 mai 2021 01h00 HE
|
ObsEva SA
-PRIMROSE 1 76-week results confirm PRIMROSE 2 data showing sustained post-treatment effects and evidence of bone mineral density (BMD) recovery following 52 weeks of treatment- -Results continue...
ObsEva Announces Enrollment Completion of Linzagolix Phase 3 EDELWEISS 3 Trial for Patients with Moderate to Severe Endometriosis-Associated Pain
04 mai 2021 01h00 HE
|
ObsEva SA
- EDELWEISS 3 trial of Yselty® expected to report topline data as planned in Q4:21- GENEVA, Switzerland and BOSTON, MA – May 4, 2021 – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a...
ObsEva SA presents posters at the ACOG Annual Clinical and Scientific Virtual Meeting April 30 - May 2, 2021
30 avr. 2021 16h05 HE
|
ObsEva SA
GENEVA, Switzerland and BOSTON, MA – April 30, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN) a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive...
ObsEva Provides Business Outlook for 2021
10 févr. 2021 01h00 HE
|
ObsEva SA
GENEVA, Switzerland and BOSTON, MA (February 10, 2021) – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s...
ObsEva Provides Update on Yselty® (Linzagolix) Clinical Development Program
11 janv. 2021 01h00 HE
|
ObsEva SA
- European Medicines Agency Validates Yselty MAA for Uterine Fibroids; US NDA Planned for 1H 2021 - Phase 3 EDELWEISS 3 (Conducted in Europe and US) Study of Yselty for Treatment of...
ObsEva Announces Additional Phase 3 PRIMROSE 1 and 2 Study Results Confirming Sustained Efficacy and Continued Safety of linzagolix in the Treatment of Uterine Fibroids
10 déc. 2020 01h00 HE
|
ObsEva SA
PRIMROSE 1 52-week results confirm the sustained efficacy and continued safety of linzagolix (Yselty®), with a potential best-in-class high-dose option (200 mg with add-back therapy [ABT]) Show...